Shenzhen Hepalink Pharmaceutical Co Ltd Net Asset Quality Index
Shenzhen Hepalink Pharmaceutical Co Ltd net asset quality index. Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a Net Asset Quality Index of 71.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥17.01 Billion minus total liabilities of CN¥4.78 Billion yields net assets of CN¥12.23 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Shenzhen Hepalink Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
Net asset quality index of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025. This chart shows how Shenzhen Hepalink Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 20 annual periods from 2006 to 2025. As of March 2026, the index stands at 71.9%, representing net assets of CN¥12.23 Billion against total assets of CN¥17.01 Billion CNY. Check Shenzhen Hepalink Pharmaceutical Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Shenzhen Hepalink Pharmaceutical Co Ltd Net Asset Quality Index by Year (2006–2025)
Shenzhen Hepalink Pharmaceutical Co Ltd net asset quality index by year from 2006 to 2025. The table below presents the year-by-year Net Asset Quality Index for Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Shenzhen Hepalink Pharmaceutical Co Ltd stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 72.6% | CN¥12.08 Billion | CN¥16.63 Billion | CN¥4.55 Billion | ▲ +2.3 pp |
| 2024 | 70.4% | CN¥12.20 Billion | CN¥17.34 Billion | CN¥5.14 Billion | ▲ +7.9 pp |
| 2023 | 62.4% | CN¥11.99 Billion | CN¥19.20 Billion | CN¥7.22 Billion | ▲ +2.8 pp |
| 2022 | 59.6% | CN¥12.41 Billion | CN¥20.81 Billion | CN¥8.41 Billion | ▼ -0.7 pp |
| 2021 | 60.3% | CN¥11.52 Billion | CN¥19.11 Billion | CN¥7.58 Billion | ▼ -1.1 pp |
| 2020 | 61.4% | CN¥11.69 Billion | CN¥19.03 Billion | CN¥7.34 Billion | ▲ +12.4 pp |
| 2019 | 49.0% | CN¥7.47 Billion | CN¥15.24 Billion | CN¥7.77 Billion | ▲ +3.3 pp |
| 2018 | 45.7% | CN¥6.24 Billion | CN¥13.66 Billion | CN¥7.41 Billion | ▼ -12.5 pp |
| 2017 | 58.3% | CN¥7.69 Billion | CN¥13.19 Billion | CN¥5.50 Billion | ▼ -4.4 pp |
| 2016 | 62.6% | CN¥8.09 Billion | CN¥12.91 Billion | CN¥4.83 Billion | ▼ -9.6 pp |
| 2015 | 72.3% | CN¥8.79 Billion | CN¥12.17 Billion | CN¥3.38 Billion | ▼ -11.9 pp |
| 2014 | 84.1% | CN¥8.35 Billion | CN¥9.93 Billion | CN¥1.58 Billion | ▼ -13.4 pp |
| 2013 | 97.5% | CN¥8.07 Billion | CN¥8.27 Billion | CN¥203.80 Million | ▲ +0.1 pp |
| 2012 | 97.4% | CN¥8.05 Billion | CN¥8.26 Billion | CN¥214.53 Million | ▼ -1.8 pp |
| 2011 | 99.2% | CN¥7.91 Billion | CN¥7.97 Billion | CN¥59.98 Million | ▲ +0.5 pp |
| 2010 | 98.7% | CN¥8.02 Billion | CN¥8.13 Billion | CN¥103.44 Million | ▲ +21.0 pp |
| 2009 | 77.7% | CN¥1.07 Billion | CN¥1.38 Billion | CN¥306.33 Million | ▲ +24.6 pp |
| 2008 | 53.2% | CN¥307.83 Million | CN¥578.92 Million | CN¥271.09 Million | ▼ -3.6 pp |
| 2007 | 56.8% | CN¥146.44 Million | CN¥257.73 Million | CN¥111.28 Million | ▲ +30.7 pp |
| 2006 | 26.2% | CN¥91.33 Million | CN¥349.01 Million | CN¥257.68 Million | — |